Annovis Bio, Inc.
2.2000+0.10 (+4.76%)
Oct 29, 4:00:02 PM EDT · NYSE · ANVS · USD
Key Stats
Market Cap
51.27MP/E (TTM)
-Basic EPS (TTM)
-2.10Dividend Yield
0%Recent Filings
8-K
8-K
Annovis prices $6M offering
Annovis Bio priced a $6 million registered direct offering on October 10, 2025, selling 3.15 million common shares at $1.50 each and pre-funded warrants for 850,000 more, closing around October 14. Funds will fuel Phase 3 trials of Buntanetap for Alzheimer's while covering working capital. Directors and officers locked up shares for 45 days post-close. Yet dilution looms large.
8-K
Annovis names new CFO
Annovis Bio appointed Mark Guerin as CFO effective September 25, 2025, bringing his biopharma finance expertise from Onconova Therapeutics to steer the company through buntanetap's late-stage trials for Alzheimer's and Parkinson's. Guerin will earn a $450,000 base salary, 40% target bonus, and options for 200,000 shares, plus six months' severance. This hire bolsters financial oversight amid promising clinical progress. Forward-looking statements highlight risks in SEC filings.
8-K
CFO resigns; CEO takes interim role
Annovis Bio's VP of Finance Andrew Walsh resigned effective August 22, 2025, without any disagreements over operations or policies. CEO Maria Maccecchini steps in as Acting CFO starting August 15, while the board hunts for a permanent replacement. Leadership shuffle signals interim stability amid the biotech's ongoing trials. No financial impacts disclosed.
8-K
Annovis Q2 results and AD trial update
Annovis Bio reported Q2 2025 financials on August 12, showing cash at $17.1 million, up from $10.6 million year-end, while R&D expenses dipped to $5.2 million from $5.8 million, narrowing net loss to $0.32 per share versus $0.44. The Phase 3 Alzheimer's trial ramps up with 76 U.S. sites and 38 patients dosed, screen failures at 50%. Patents now fully cover crystal buntanetap globally. Enrollment pushes forward.
ANAB
AnaptysBio, Inc.
36.12-0.04
ANEB
Anebulo Pharmaceuticals, Inc.
2.71+0.02
ANNX
Annexon, Inc.
3.19-0.26
ANRO
Alto Neuroscience, Inc.
14.04+0.42
ANTX
AN2 Therapeutics, Inc.
1.30+0.01
AVXL
Anavex Life Sciences Corp.
8.02-0.08
BIVI
BioVie Inc.
1.80-0.06
KLTO
Klotho Neurosciences, Inc.
0.52-0.01
NNNN
Anbio Biotechnology
21.65-1.69
NUVB
Nuvation Bio Inc.
5.26-0.11